This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$46.70 -0.38 | -0.81%
11/30/15 - 4:01:00 PM ET
  • Prev Close: 47.08
  • Day's Open: 47.08
  • Volume: 3.40M
  • Shares Outstanding: 497.92M
  • Mkt Cap: 23.39B
  • Div: --
  • Div Yield: --
ZTS Day's Range
ZTS 52 Week Range
ZTS Business Summary
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide.View ZTS key stats
Zoetis Inc. Class A - ZTS - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Zoetis Inc. Class A as a Hold with a ratings score of C-.
Report Snippet: We rate ZOETIS INC (ZTS) a HOLD. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet.
Rating: 2.33 out of 5, 'C-' Hold.
You can view the full analysis from the report here:
ZTS Rating Report
ZTS Earnings Transcripts
  • Zoetis (ZTS) Earnings Report: Q3 2015 Conference Call Transcript
    TheStreet | 11/03/15 - 02:11 PM EST
  • Zoetis (ZTS) Earnings Report: Q2 2015 Conference Call Transcript
    TheStreet | 08/05/15 - 08:48 AM EDT
  • Zoetis (ZTS) Earnings Report: Q1 2015 Conference Call Transcript
    TheStreet | 05/06/15 - 05:53 AM EDT
  • Zoetis (ZTS) Earnings Report: Q4 2014 Conference Call Transcript
    TheStreet | 02/11/15 - 01:42 PM EST
ZTS Percentage in these ETFs
ZTS News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ZTS Zoetis Inc. Class A

Chart of ZTS

Analysts Ratings for ZTS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy
Moderate Buy
Moderate Sell
Strong Sell

ZTS Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs